Entries of Arnold, D. on the publication server

Al-Batran, S., Hofheinz, R., Homann, N., Illerhaus, G., Martens, U. M., Stoehlmacher-Williams, J., Schmalenberg, H., Luley, K. B., Prasnikar, N., Egger, M., Probst, S., Hartmann, J. T., Moehler, M. H., Arnold, D., Fischbach, W., Pauligk, C., Moenig, S. P., Piso, P. and Jaeger, E. (2011) Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Journal of Clinical Oncology 29 (15_sup), p. 4070. Fulltext not available.

Liersch, T., Weiss, C., Dellas, K., Hipp, M., Sauer, R., Rödel, C. and Arnold, D. (2011) Effect of pathohistologic complete remission (pCR) rate on the prediction of long-term prognosis following chemoradiotherapy (XRT) with cetuximab (Cet), capecitabine (CAP), and oxaliplatin (OX; Cet-CAPOX) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology 29 (15_sup), e14035-e14035. Fulltext not available.

Dellas, K., Roedel, F., Arnold, D., Kappler, M., Hipp, M., Bataille, F., Vordermark, D., Roedel, C. and Hartmann, A. (2010) EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology 28 (15_sup), p. 3653. Fulltext not available.

Knoedler, M., Gauler, T. C., Matzdorff, A., Dietz, A., Gruenwald, V., Arnold, D., Hennemann, B., Schroeder, M., Hofele, C. , Schmittel, A. and Keilholz, U. (2008) Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer. Journal of Clinical Oncology 26 (15_sup), p. 6066. Fulltext not available.

Roedel, C., Arnold, D., Hipp, M. and Sauer, R. (2006) 147. International Journal of Radiation Oncology*Biology*Physics 66 (3), S82-S83. Fulltext not available.